Trial · NCT00382408
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Vaccine | 1 | participants | ||
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Placebo | 48 | participants | ||
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort | Vaccine | 1 | participants | ||
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort | Placebo | 47 | participants | ||
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56 | Vaccine | 0 | participants | ||
| Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort --- Day 11-56 | Placebo | 44 | participants | ||
| Percentage of Participants Showing ADV-7 Seroconversion at Week 4 | Vaccine | 93.8 | 95% Confidence Interval 92.4 to 95.2 | percentage of participants | |
| Percentage of Participants Showing ADV-7 Seroconversion at Week 4 | Placebo | 5.3 | 95% Confidence Interval 3.0 to 7.6 | percentage of participants | |
| Percentage of Participants Showing ADV-4 Seroconversion at Week 4 | Vaccine | 94.5 | 95% Confidence Interval 93.4 to 95.5 | percentage of participants | |
| Percentage of Participants Showing ADV-4 Seroconversion at Week 4 | Placebo | 10.6 | 95% Confidence Interval 8.2 to 12.9 | percentage of participants | |
| Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Vaccine | 3 | participants | ||
| Number of Participants With Wild Type-4 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Placebo | 65 | participants | ||
| Percentage of Participants Showing ADV Type-4 Booster at Week 4 | Vaccine | 50.3 | 95% Confidence Interval 47.3 to 53.2 | percentage of participants | |
| Percentage of Participants Showing ADV Type-4 Booster at Week 4 | Placebo | 0.6 | 95% Confidence Interval -0.2 to 1.5 | percentage of participants | |
| Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Vaccine | 0 | participants | ||
| Number of Participants With Wild Type-7 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Placebo | 0 | participants | ||
| Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Vaccine | 0 | participants | ||
| Number of Participants With Wild Type-7 Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort | Placebo | 0 | participants | ||
| Percentage of Participants Showing ADV Type-7 Booster at Week 4 | Vaccine | 46.1 | 95% Confidence Interval 43.8 to 48.4 | percentage of participants | |
| Percentage of Participants Showing ADV Type-7 Booster at Week 4 | Placebo | 3.9 | 95% Confidence Interval 2.4 to 5.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00382408/results